CJC-1295 with DAC

CJC-1295 with DAC 2 mg — the long-acting standard in GH-axis research
A growth hormone releasing hormone analogue built for longevity in the bloodstream. The Drug Affinity Complex sets CJC-1295 with DAC apart from its short-acting counterpart and makes it a staple reference peptide in endocrine signalling studies.

What is CJC-1295 with DAC?

CJC-1295 is a synthetic analogue of growth hormone releasing hormone (GHRH), modified at several amino acid positions to resist enzymatic breakdown. The DAC variant adds a Drug Affinity Complex — a maleimide group that binds covalently to serum albumin — dramatically extending its circulating half-life relative to the non-DAC form. For researchers, that extended exposure profile is the entire point: it allows investigation of sustained GHRH receptor engagement on the pituitary rather than the sharp, transient pulses produced by short-acting secretagogues.

Research interest

• GH pulsatility — studied for how prolonged receptor occupancy alters the natural pulsatile architecture of growth hormone release.
• Endocrine feedback loops — of interest to researchers examining pituitary-hypothalamic signalling and downstream IGF-1 dynamics.
• Half-life engineering — a textbook example of albumin-binding as a strategy for extending peptide persistence, frequently cited in peptide design literature.
• Comparative secretagogue work — commonly paired with GHRP-class compounds in studies mapping synergistic versus independent receptor pathways.
• Recovery and tissue-turnover models — investigated in preclinical contexts concerned with GH-mediated anabolic signalling.

Its stability profile also makes CJC-1295 with DAC a practical laboratory tool: fewer handling events and a more forgiving experimental window than rapidly cleared analogues. Purity remains critical, as GHRH-receptor assays are highly sensitive to truncated or oxidised peptide fragments.

Specifications

• Content: 2 mg of active substance per vial
• Form: Lyophilised powder (vial)
• Purity: Pharmaceutical-grade, batch-tested and lot-traceable
• Presentation: Sealed, tamper-evident single vial
• Storage: -20 °C sealed; 2-8 °C short-term

Handling & storage

Lyophilised material is best held at -20 °C in the sealed, unopened vial. Refrigeration at 2-8 °C is acceptable for short-term handling. Protect from light, humidity and repeated freeze-thaw exposure. Handle the lyophilisate dry and sealed until the moment of use. Once reconstituted with a suitable sterile diluent under the laboratory's own validated procedure, the solution should be kept refrigerated, protected from light, and not subjected to vigorous agitation, which can shear peptide chains.

Why researchers buy from Rogue

• Batch-tested, not batch-guessed — purity and identity verified before a vial is ever listed.
• Authentic European sourcing — a short, controlled supply chain with sealed, tamper-evident vials.
• Consistency across orders — lot-to-lot control so repeat work stays comparable.
• Fast, tracked, discreet — quick EU-wide dispatch in unmarked packaging.

For research purposes only. Not a medicinal product. Not for human or veterinary consumption. Intended for qualified laboratory research use only. No statement on this page is a medical claim, and no administration, dosing or protocol guidance is offered or implied.

Related: Peptides · GHRP-2 10 mg · GHK-Cu 100 mg · GHRP-6 10 mg